Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00280423 · ClinicalTrials.gov registry record · Phase 2

Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia

A Phase 2 study of Insomnia and Sleep Initiation and Maintenance Disorders, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
342
Enrollment target
20
Study locations

NCT00280423 is a Phase 2 study of Insomnia and Sleep Initiation and Maintenance Disorders that has completed, run by GlaxoSmithKline. The registered enrollment target is 342 participants, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (104% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00280423, a Phase 2 study of Insomnia and Sleep Initiation and Maintenance Disorders, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
342 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to find the optimal (best) doses of GW679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.

Conditions Studied

Insomnia Sleep Initiation and Maintenance Disorders

Interventions

  • DRUG GW679769

Study Locations (20)

California

  • GSK Investigational Site - Burbank
  • GSK Investigational Site - Huntington Beach
  • GSK Investigational Site - Irvine
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - National City
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - San Francisco
  • GSK Investigational Site - Santa Rosa

Florida

  • GSK Investigational Site - DeLand
  • GSK Investigational Site - Delray Beach
  • GSK Investigational Site - Hallandale
  • GSK Investigational Site - Largo
  • GSK Investigational Site - Miami

Arizona

  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Tucson

Alabama

  • GSK Investigational Site - Birmingham

Arkansas

  • GSK Investigational Site - Little Rock

Connecticut

  • GSK Investigational Site - Norwalk

Trial Details

FieldValue
Enrollment Target 342 participants
Start Date 2006-01
Est. Completion 2007-02
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00280423

The ClinicalTrials.gov registry entry for NCT00280423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (104% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which GW679769 is the first listed.

NCT00280423 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00280423 about?

NCT00280423 is a clinical study titled "Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia". This study is designed to find the optimal (best) doses of GW679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.

What is the current status of trial NCT00280423?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 342 participants. The study started on 2006-01. Estimated completion is 2007-02.

What conditions does trial NCT00280423 study?

This clinical trial studies the following conditions: Insomnia, Sleep Initiation and Maintenance Disorders.

What interventions are being tested in trial NCT00280423?

The interventions under investigation include: GW679769 (DRUG).

Who is sponsoring clinical trial NCT00280423?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00280423 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Insomnia

All registered trials for this condition

Sleep Initiation and Maintenance Disorders

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.